Available Evidence on Marijuana's Cardiovascular Effects Is Scant

Share this content:
Available Evidence on Marijuana's Cardiovascular Effects Is Scant
Available Evidence on Marijuana's Cardiovascular Effects Is Scant

TUESDAY, Jan. 23, 2018 (HealthDay News) -- The evidence examining associations between marijuana use and cardiovascular risk factors and outcomes is limited, according to a review published online Jan. 23 in the Annals of Internal Medicine.

Divya Ravi, M.D., M.P.H., from the Wright Center for Graduate Medical Education in Scranton, Pa., and colleagues conducted a systematic literature review to identify observational studies that enrolled adults using any form of marijuana and reported on vascular risk factors (hyperglycemia, diabetes, dyslipidemia, and obesity) or on outcomes (stroke, myocardial infarction, cardiovascular mortality, and all-cause mortality in cardiovascular cohorts).

The researchers identified 13 studies examining associations between marijuana use and cardiovascular risk factors and 11 studies examining associations with clinical outcomes. Six cross-sectional studies suggested a metabolic benefit from marijuana use, but this finding was not supported by prospective studies. Recall bias, inadequate exposure assessment, minimal marijuana exposure, and a predominance of low-risk cohorts limit the current evidence base.

"Evidence examining the effect of marijuana on cardiovascular risk factors and outcomes, including stroke and myocardial infarction, is insufficient," the authors write. "Adequately powered prospective studies are needed to determine the effect of chronic marijuana use on cardiovascular health."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »